UMECLIDINIUM BROMIDE
| Brand name | INCRUSE ELLIPTA |
|---|---|
| Active ingredient | UMECLIDINIUM BROMIDE |
| Strength | EQ 0.0625MG BASE/INH |
| Dosage form | POWDER |
| Route | INHALATION |
| Modality | Small molecule |
| FDA approval | April 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 7488827 | December 2027 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.